Verona Pharma Plc Company Profile (LON:VRP)

Analyst Ratings

Consensus Ratings for Verona Pharma Plc (LON:VRP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Verona Pharma Plc (LON:VRP)
Show:
DateFirmActionRatingPrice TargetActions
1/28/2016N+1 SingerReiterated RatingCorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Verona Pharma Plc (LON:VRP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Verona Pharma Plc (LON:VRP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Verona Pharma Plc (LON:VRP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Verona Pharma Plc (LON:VRP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/20/2016Ebsworth,DavidInsiderBuy400,000GBX 3£12,000Tweet This Trade  Share This Trade on StockTwits
12/3/2015Ebsworth,DavidInsiderBuy370,000GBX 3£11,100Tweet This Trade  Share This Trade on StockTwits
6/17/2015David EbsworthInsiderBuy250,000GBX 4.70£11,750Tweet This Trade  Share This Trade on StockTwits
5/18/2015David EbsworthInsiderBuy300,000GBX 3.50£10,500Tweet This Trade  Share This Trade on StockTwits
3/3/2015David EbsworthInsiderBuy450,000GBX 2.43£10,935Tweet This Trade  Share This Trade on StockTwits
2/16/2015Biresh RoyInsiderBuy500,000GBX 2.30£11,500Tweet This Trade  Share This Trade on StockTwits
2/13/2015Sven Jan-Anders KarlssonInsiderBuy1,025,909GBX 2£20,518.18Tweet This Trade  Share This Trade on StockTwits
2/4/2015David EbsworthInsiderBuy700,000GBX 1.54£10,780Tweet This Trade  Share This Trade on StockTwits
1/19/2015Stuart BottomlyInsiderBuy1,000,000GBX 1.50£15,000Tweet This Trade  Share This Trade on StockTwits
1/13/2015David EbsworthInsiderBuy803,107GBX 1.35£10,841.94Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Verona Pharma Plc (LON:VRP)
DateHeadline
07/23/16 06:26 PMVerona Pharma : Result of General Meeting
07/23/16 06:26 PMVERONA PHARMA PLC - Result of GM
07/03/16 01:31 AMConfirmation of General Meeting Date - [at noodls] - Confirmation of General Meeting Date The text version of this document is not available at the moment. The original content was posted at original link . Verona Pharma plc published this content on 03 ...
07/02/16 09:43 AMVERONA PHARMA PLC - Notice of GM
06/28/16 06:19 AMInvestor News from Veritas Pharma
06/21/16 06:37 PMLondon stocks hold onto gains as Brexit fears fade
06/21/16 06:37 PMNASDAQ listing for Verona Pharma?
06/17/16 02:19 PMProposed Placing to raise c. £44.7 million and Notice of General Meeting - [at noodls] - Proposed Placing to raise c. £44.7 million and Notice of General Meeting The text version of this document is not available at the moment. The original content was posted at original link . Verona Pharma ...
06/17/16 02:19 PMAGM Notice & Annual Report (2) - [at noodls] - AGM Notice & Annual Report (2) The text version of this document is not available at the moment. The original content was posted at original link . Verona Pharma plc published this content on 03 June 2016 ...
06/04/16 10:23 AMVerona Pharma reports progress but losses rise
06/03/16 11:45 AMAGM Notice & Annual Report - [at noodls] - AGM Notice & Annual Report The text version of this document is not available at the moment. The original content was posted at original link . Verona Pharma plc published this content on 03 June 2016 ...
06/03/16 06:07 AMQ4 2015 Verona Pharma PLC Earnings Release - Time Not Supplied -
06/03/16 01:45 AMFinancial Results for year ended 31 December 2015 - [at noodls] - Financial Results for year ended 31 December 2015 The text version of this document is not available at the moment. The original content was posted at original link . Verona Pharma plc published this content ...
06/02/16 07:44 PMPREVIEW - All eyes on US jobs number Friday - currently 22% for June and 52% for July, unwound significantly (recall the forecast hit 32% following the release of the May minutes). Elsewhere, on the corporate front in the UK, Verona Pharma Plc (LON:VRP) will post quarterly earnings.
02/26/16 10:53 AMAnalyst Coverage Updates - Verona Pharma (LON:VRP) - Risers & Fallers - Analyst Coverage Updates - Verona Pharma (LON:VRP)Risers & FallersVerona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.
02/11/16 01:57 PMVERONA PHARMA : Grant of Share Options - 2015 VERONA PHARMA: Patient enrolment completed in RPL554 PhIIa studies 2015 VERONA PHARMA: Start of RPL554 Phase IIa combination study 2015 VERONA PHARMA: First Patients Dosed In RPL554 Combination Study
02/04/16 12:52 PMVerona Pharma Plc Just Recorded A Sigfniciant Decline - WallStreet.org - Verona Pharma Plc Just Recorded A Sigfniciant DeclineWallStreet.orgThe stock of Verona Pharma Plc (LON:VRP) is a huge mover today! The stock decreased 4.41% or GBX 0.15 on February 3, hitting GBX 3.25. About 678,710 shares traded hands. Verona Pharma Plc (LON:VRP) has declined 33.33% since July 3, 2015 and is ...and more »
01/21/16 11:33 AMVerona Pharma PLC (VRP) - 21 January 2016, Cardiff - Verona Pharma plc (AIM: VRP) received notification that on 20 January 2016 David Ebsworth, Director of the Company, purchased 400,000 ordinary shares of 0.1 pence each of the Company ("Ordinary Shares") at a price of 2.5 pence ...
10/14/15 07:31 AMStart of RPL554 Phase IIa combination study - [at noodls] - Verona Pharma... This is an abstract of the original noodl. To continue reading this document, click here for the original version.
09/29/15 05:57 AMPositive headline data from RPL554 clinical study in COPD patients - [at noodls] - New suspension formulation is well tolerated; results signal marked improvement in lung function RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016 29 September 2015, Cardiff - ...
06/11/15 03:06 AMFurther RPL544 Phase 2a trial commences - [at noodls] - First asthma patients dosed with RPL554 in new proprietary nebulised formulation 11 June 2015, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines ...
06/08/15 02:37 AMRPL554 MAD study in COPD patients commences - [at noodls] - 8 June 2015, Cardiff - Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces the successful completion of the second ...
05/13/15 11:07 AMNotice of posting 2014 Annual Report - [at noodls] - Notice of posting 2014 Annual Report
05/12/15 02:38 AMAudited Results for the 12 months ended 31 December 2014 - [at noodls] - Audited Results for the 12 months ended 31 December 2014

Social

About Verona Pharma Plc

Verona Pharma Plc logoVerona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its program is RPL554, an inhaled, dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors, as a nebulized treatment for patients in hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL554 has completed two double-blind placebo controlled randomized Phase II b studies of RPL554: one in mild to moderate asthma and another in mild to moderate COPD. Its other products include VRP700 and NAIPs. VRP700 is an anti-tussive (cough) drug and has completed a Phase II trial. The Company's subsidiaries include Rhinopharma Limited and Verona Pharma Inc.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: VRP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.04
  • 50 Day Moving Average: $3.12
  • 200 Day Moving Average: $3.26
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $30.80M
  • Current Year EPS Consensus Estimate: $-0.41 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: